Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2865 - Prognostic ability of HR-QoL parameters in metastatic renal cell carcinoma (mRCC)


09 Oct 2016


Poster display


Viktor Grünwald


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


V. Grünwald1, M. Dietrich2, G.R. Pond3

Author affiliations

  • 1 Clinic For Hematology, Hemostasis, Oncology And Stemcelltransplantation, Hannover Medical School, 30625 - Hannover/DE
  • 2 Natural Sciences, Leibniz University Hannover, Hannover/DE
  • 3 Oncology, Escarpment Cancer Research Institute, McMaster Medical Centre, Hamilton/CA


Abstract 2865


MSKCC and IMDC risk classification scores consist of clinical and laboratory parameters, which are able to classify patients prognosis. Baseline health related quality of life (HR-QoL) has been previously shown to have prognostic relevance in cancers. We therefore tested whether the addition of HR-QoL parameters to these tools can improve prognostic accuracy.


1100 1st line patients treated with sunitinib or pazopanib within the COMPARZ study (NCT00720941) were analyzed retrospectively. Baseline FACIT-Fatigue (F), FKSI-19 and the DRS-P subscale were used as continuous variable in prognostic factor analysis. Cox proportional hazards regression was performed to evaluate the potential prognostic ability of HR-QoL parameters on OS. Scores were adjusted for MSKCC and IMDC risk group scores separately.


Univariable analysis on prognosis, adjusted for risk groups.

HR (CI95%) P
IMDC risk FACIT-F Favorable Intermediate Unfavorable Unknown Continuous 0.77 (0.37, 1.60) 1.42 (0.70, 2.87) 3.10 (1.50, 6.38) REFERENCE 0.97 (0.97, 0.98)


Our analyses indicate that baseline HR-QoL scores add to established risk prognosticators. However, only a single HR-QoL score should be used for further validation. Further study of discrimination ability is ongoing.

Clinical trial identification


Legal entity responsible for the study

GSK sponsored clinical study, which is the data set for the current retrospective analysis


Medical School Hannover, Leibniz University, McMaster University


V. Grünwald: Honoraria: BMS, Novartis, Pfizer. Consultation: BMS, Novartis, Pfizer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.